Enhanced type 1 interferon signature in axial spondyloarthritis patients unresponsive to secukinumab treatment
Arthritis Rheumatol 2024 Epub ahead of print doi: 10.1002/art.42974
Pacheco et al. demonstrated that, compared with axSpA patients who respond to secukinumab, patients who do not respond show increased IL-17A-producing cells and have a more pronounced type 1 IFN signature, indicating a larger inflammatory burden.
The study aimed to distinguish clinical and immune cellular profiles between secukinumab treatment responders and secukinumab nonresponders, to better predict treatment outcomes in axial spondyloarthritis.
Keywords:
